➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Colorcon
McKinsey
Moodys

Last Updated: July 31, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GASMOTIN


Email this page to a colleague

« Back to Dashboard

Clinical Trials for Gasmotin

Trial ID Title Status Sponsor Phase Summary
NCT01274793 ↗ Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy Recruiting Guangzhou University of Traditional Chinese Medicine Phase 1 the objective of this study is to investigate the Dose-Effect Relationship of Acupuncture with Two-ways Regulation Effect to Treat Functional Enteropathy
NCT01274793 ↗ Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy Recruiting The Fifth Hospital of Wuhan Phase 1 the objective of this study is to investigate the Dose-Effect Relationship of Acupuncture with Two-ways Regulation Effect to Treat Functional Enteropathy
NCT01274793 ↗ Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy Recruiting Wuhan Union Hospital, China Phase 1 the objective of this study is to investigate the Dose-Effect Relationship of Acupuncture with Two-ways Regulation Effect to Treat Functional Enteropathy
NCT01274793 ↗ Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy Recruiting Huazhong University of Science and Technology Phase 1 the objective of this study is to investigate the Dose-Effect Relationship of Acupuncture with Two-ways Regulation Effect to Treat Functional Enteropathy
NCT01284764 ↗ Efficacy Study of a Low Volume of Water Intake and Mosapride for Endoscopy in Patients With Subtotal Gastrectomy Completed Inje University Phase 3 A low volume of water intake and mosapride will effectively reduce food residue in remnant stomach for patients who had undergone subtotal gastrectomy due to gastric cancer.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Gasmotin

Condition Name

Condition Name for
Intervention Trials
Functional Dyspepsia 3
Functional Constipation 2
Foreign Body Left During Endoscopic Examination 1
Healthy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Dyspepsia 4
Gastritis 4
Constipation 2
Cholelithiasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gasmotin

Trials by Country

Trials by Country for
Location Trials
Korea, Republic of 6
China 2
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gasmotin

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 1 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 6
Unknown status 3
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gasmotin

Sponsor Name

Sponsor Name for
Sponsor Trials
Daewoong Pharmaceutical Co. LTD. 3
Huazhong University of Science and Technology 2
Liangzhou Wei 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Other 9
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Dow
Mallinckrodt
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.